High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study

dc.contributor.authorTalvitie EM
dc.contributor.authorVilhonen H
dc.contributor.authorKurki S
dc.contributor.authorKarlsson A
dc.contributor.authorOrte K
dc.contributor.authorAlmangush A
dc.contributor.authorMohamed H
dc.contributor.authorLiljeroos L
dc.contributor.authorSingh Y
dc.contributor.authorLeivo I
dc.contributor.authorLaitinen T
dc.contributor.authorKallajoki M
dc.contributor.authorTaimen P
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=keuhkosairausoppi ja kliininen allergologia|en=Pulmonary Diseases and Clinical Allergology|
dc.contributor.organizationfi=lääketieteellinen tiedekunta|en=Faculty of Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.13290506867
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code1.2.246.10.2458963.20.92467408925
dc.contributor.organization-code2607000
dc.contributor.organization-code2607100
dc.contributor.organization-code2607308
dc.converis.publication-id48886248
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/48886248
dc.date.accessioned2022-10-28T14:21:24Z
dc.date.available2022-10-28T14:21:24Z
dc.description.abstractObjectives: Tumor mutation burden (TMB) is an emerging predictive cancer biomarker. Few studies have addressed the prognostic role of TMB in non-small cell lung carcinoma, with conflicting results. Moreover, the association of TMB with different histological subtypes of lung adenocarcinoma has hitherto not been systematically evaluated. Here we studied the prognostic value of TMB and its distribution in different histological subtypes of lung adenocarcinomas in a retrospective cohort using the most recent updated classification guidelines.Materials and methods: 176 surgically resected stage I-IV lung adenocarcinomas were histologically reclassified according to WHO 2015 guidelines. A modified classification subdividing the acinar subtype into classic acinar, complex glandular and cribriform subtypes was further applied and potentially prognostic histopathological characteristics such as tumor-infiltrating lymphocytes were evaluated. 148 patients with stage I-III tumors and complete follow-up data were included in the survival analyses. TMB was determined by a commercial next generation sequencing panel from 131 tumors, out of which 105 had survival data available.Results: Predominant micropapillary, solid and complex glandular as well as nonpredominant cribriform histological subtypes were associated with significantly shorter survival. High TMB concentrated in micropapillary, solid and acinar predominant subtypes. Interestingly, TMB >= 14 mutations/MB conferred a stage- and histology-independent survival benefit compared to TMB < 14 in multivariable analysis for overall (HR 0.284, 95% CI 0.14-0.59, P=0.001) and disease-specific survival (HR 0.213, 95% CI 0.08-0.56, P=0.002).Conclusion: TMB was an independent biomarker of favorable prognosis in our cohort of lung adenocarcinoma despite being associated with predominant histological subtypes considered aggressive.
dc.format.pagerange333
dc.format.pagerange342
dc.identifier.jour-issn1522-8002
dc.identifier.olddbid187781
dc.identifier.oldhandle10024/170875
dc.identifier.urihttps://www.utupub.fi/handle/11111/43254
dc.identifier.urnURN:NBN:fi-fe2021042826211
dc.language.isoen
dc.okm.affiliatedauthorTalvitie, Eva-Maria
dc.okm.affiliatedauthorVilhonen, Heikki
dc.okm.affiliatedauthorKurki, Samu
dc.okm.affiliatedauthorKarlsson, Antti
dc.okm.affiliatedauthorLeivo, Ilmo
dc.okm.affiliatedauthorLaitinen, Tarja
dc.okm.affiliatedauthorKallajoki, Markku
dc.okm.affiliatedauthorTaimen, Pekka
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherELSEVIER SCIENCE INC
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1016/j.neo.2020.05.004
dc.relation.ispartofjournalNeoplasia
dc.relation.issue9
dc.relation.volume22
dc.source.identifierhttps://www.utupub.fi/handle/10024/170875
dc.titleHigh tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study
dc.year.issued2020

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S1476558620301214-main.pdf
Size:
1.6 MB
Format:
Adobe Portable Document Format
Description:
Publisher's PDF (CC BY NC ND)